Adapt AO outperforms conventional lens

Article

At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL.

At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL, according to Ann Haustermans, Belgium.

The multicentre, prospective, intra-individual, comparative study enrolled 69 patients requiring bilateral cataract surgery. One eye of each subject received the Adapt AO and the other the spherical Akreos Adapt lens. Follow-up data was collected at one and three months and one and two years, and patients completed a questionnaire assessing their quality of vision at three months.

At one-month follow-up, the Adapt AO performed significantly better in low contrast UCVA (p=0.03) and BCVA (p=0.047). It was also found to perform better than the spherical Adapt at all spatial frequencies in photopic contrast sensitivity and at 1, 5 and 6 cpd in mesopic contrast sensitivity. At three-months follow-up, the lenses performed equally but at one year the Adapt AO performed better in high contrast UCVA and BCVA.

Dr Haustermanns concluded that the aspheric Akreos Adapt AO lens offers better optical performance than the conventional spherical Adapt IOL.

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.